Damora Therapeutics, Inc. (DMRA)

Market Cap	1.46B +27,892.2%
Revenue (ttm)	n/a
Net Income	-209.84M
EPS	-153.95
Shares Out	60.30M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	240,980
Open	25.83
Previous Close	25.50
Day's Range	23.41 - 26.17
52-Week Range	2.01 - 38.33
Beta	1.57
Analysts	Buy
Price Target	46.00 (+89.53%)
Earnings Date	Apr 30, 2026

About DMRA

Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatmen...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 29, 2020
• Employees: 7
• Stock Exchange: NASDAQ
• Ticker Symbol: DMRA
• Website: https://www.damoratx.com

Analyst Summary

According to one analyst, the rating for DMRA stock is "Buy" and the 12-month stock price target is $46.0.

Price Target

$46.0

(89.53% upside)

Analyst Consensus: Buy